Nemaura Medical Inc. Stock

Equities

NMRD

US6404422080

Medical Equipment, Supplies & Distribution

Delayed OTC Markets 03:18:38 2024-04-18 pm EDT 5-day change 1st Jan Change
0.0798 USD +5.00% Intraday chart for Nemaura Medical Inc. -9.32% -63.56%
Sales 2024 * 200K Sales 2025 * 1.4M Capitalization 3.07M
Net income 2024 * -9M Net income 2025 * -12M EV / Sales 2024 * 15.3 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.19 x
P/E ratio 2024 *
-0.24 x
P/E ratio 2025 *
-0.17 x
Employees 36
Yield 2024 *
-
Yield 2025 *
-
Free-Float 51.38%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.00%
1 week-9.32%
Current month-10.34%
1 month-0.25%
3 months+2.31%
6 months-73.88%
Current year-63.56%
More quotes
1 week
0.07
Extreme 0.073
0.10
1 month
0.07
Extreme 0.071
0.10
Current year
0.07
Extreme 0.068
0.21
1 year
0.07
Extreme 0.068
1.25
3 years
0.07
Extreme 0.068
17.40
5 years
0.07
Extreme 0.068
17.40
10 years
0.07
Extreme 0.068
96.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 13-12-23
Chief Operating Officer 47 22-01-04
Chief Tech/Sci/R&D Officer 53 -
Members of the board TitleAgeSince
Chief Executive Officer 50 13-12-23
More insiders
Date Price Change Volume
24-04-18 0.0798 +5.00% 27 920
24-04-17 0.076 +2.56% 29,402
24-04-16 0.0741 -0.54% 28,054
24-04-15 0.0745 -12.35% 16,268
24-04-12 0.085 -3.41% 403

Delayed Quote OTC Markets, April 18, 2024 at 03:18 pm EDT

More quotes
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The Company is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.076 USD
Average target price
1.5 USD
Spread / Average Target
+1,873.68%
Consensus